Physiology of the adult can be modified by alterations in prenatal development driven by the maternal environment. Developmental programming, which can be established before the embryo implants in the uterus, can affect females differently than males. The mechanism by which sex-specific developmental programming is established is not known. Here we present evidence that maternal regulatory signals change female embryos differently than male embryos. In particular, actions of the maternally derived cytokine CSF2 from Day 5 to Day 7 of development affected characteristics of the embryo at Day 15 differently for females than males. CSF2 decreased length and IFNT secretion of female embryos but increased length and IFNT secretion of male embryos. Analysis of a limited number of samples indicated that changes in the transcriptome and methylome caused by CSF2 also differed between female and males. Thus, sex-specific programming by the maternal environment could occur when changes in secretion of maternally derived regulatory molecules alter development of female embryos differently than male embryos.
INTRODUCTION
Physiological function and health of the adult is first established during prenatal life: alterations in the maternal environment can lead to changes in the adult that include susceptibility to hypertension, diabetes, cardiovascular disease, and various cancers [1] [2] [3] [4] . Programming of development occurs as early as the preimplantation period. Feeding pregnant female mice or rats a low-protein diet for a limited period corresponding to preimplantation development caused changes in the offspring that persisted into adult life [5] [6] [7] . Similarly, postnatal physiology and immune function were altered in sheep derived from mothers fed a diet deficient in cobalt and sulfur for 8 wk before and 6 days after mating [8] . Furthermore, embryos that develop in vitro give rise to neonates that have increased likelihood for a variety of abnormalities, as shown in humans [9, 10] , cows [11, 12] , sheep [12] , and mice [13, 14] .
One of the characteristics of developmental programming in the preimplantation period is that female embryos are programmed differently than male embryos [15] . In mice, for example, feeding a low-protein diet during the first 3.5 days following conception affected females differently than males. Postnatal growth and body size was affected by protein diet in female offspring but not male offspring [5, 6] . At adulthood, females from mothers fed low-protein diets had altered behavioral scores [5] , increased blood pressure [6] , and reduced heart to body weight ratio [5] as compared to animals born from control females. These traits were not affected in male offspring, but males from low-protein mothers had elevated lung angiotensin-converting enzyme [16] . In rats, feeding a methyl-deficient diet for 3 wk prior to mating and 5 days after gestation increased the concentration of insulin in male but not female offspring [17] .
Developmental plasticity in response to maternal environment has been proposed as an evolutionary strategy to allow individuals to adapt to transient changes in environment while preserving genotype [4] . Sexual dimorphism in developmental programming may reflect the fact that relative value of females and males for reproductive fitness varies with environment [18] .
The mechanism by which a change in maternal environment alters the developmental program of a female embryo differently than that of a male embryo is not known. One possibility is that female embryos respond differently to maternally derived molecules that regulate embryonic development (hereafter termed embryokines) than do male embryos. If so, alteration in secretion of maternal embryokines in response to environmental change could result in a sex-specific deviation in the developmental program. The possibility of differential responsiveness to maternal embryokines is strengthened by observations that gene expression is different between female and male embryos as early as the blastocyst stage [19, 20] .
Colony-stimulating factor 2 is a good candidate as an embryokine responsible for sex-specific programming. This cytokine is produced by the oviductal and endometrial epithelium of a wide range of mammals, including mice [21] , cattle [22] and humans [23] . Treatment of preimplantation embryos with CSF2 leads to an increase in number and pluripotency of cells of the inner cell mass [24] [25] [26] , altered gene expression [27] , and increased resistance to apoptosis [28] . That CSF2 is capable of altering the developmental program of the embryo is indicated by findings that bovine [25] , mouse [29] , and human [30] embryos treated with CSF2 have increased likelihood to survive to term when transferred into females. Endometrial secretion of CSF2 also changes in response to maternal environment, as indicated by experiments showing reduced expression of CSF2 in endometrium of obese cows [31] and increased secretion of CSF2 after induction of inflammation in mice [32] .
Culture of bovine embryos with CSF2 from Day 5 to Day 7 of development resulted in alterations in characteristics of the embryo at a later time point [25, 27] . In particular, embryos treated with CSF2 tended to be longer and produce more of the antiluteolytic signal IFNT at Day 15 of development than control embryos. For the experiment reported here, we used this model of CSF2-mediated developmental programming to explore whether such changes in the trajectory of development depend upon sex. Day 15 is an important point in time for the survival of the bovine embryo. At this time, the extraembryonic membranes (EEM) of the embryo are in the process of extensive elongation so that the embryo increases ;50-fold in length between Day 13 and Day 16 [33] . Coincident with elongation of the EEM is activation of transcription of IFNT by trophoblast, which encodes for a type I interferon that acts on the endometrium to block secretion of prostaglandin F 2a and thereby ensure survival of the corpus luteum and continued progesterone secretion [34] .
The results presented here indicate that the consequences of exposure to CSF2 from Day 5 to Day 7 of development are fundamentally different for the female and male embryo at Day 15 with respect to embryo elongation, IFNT secretion, and characteristics of the transcriptome and methylome. These results support the contention that sexual dimorphism in response to maternal embryokines is an important mechanism for establishment of sex differences in developmental programming.
MATERIALS AND METHODS

Embryo Production
In vitro production of bovine embryos was performed as previously described [35] unless otherwise noted. Briefly, cumulus-oocyte complexes (COCs) from Holstein females were purchased from either Sexing Technologies or Ovitra. The COCs were shipped overnight at 398C in a portable incubator while cultured in a proprietary maturation medium. Once arrived, groups of 20-35 matured oocytes were fertilized with Percoll-purified sperm (1.0 3 10 6 /ml) from a single Holstein bull for 8 h at 38.58C in 1.7 ml of SOF-FERT [36] . Cumulus cells were denuded after fertilization by vortexing in 600 ll HEPES-TALP containing 1000 U/ml hyaluronidase. Putative zygotes were then cultured in groups of 30 in 45-ll microdrops of SOF-BE1 [35] covered with mineral oil at 38.58C in a humidified atmosphere of 5% (v/v) O 2 and 5% (v/v) CO 2 with the balance N 2 . Cleavage rate was assessed at Day 3 postinsemination. On Day 5 postinsemination, drops were supplemented with either 5 ll recombinant bovine CSF2 (Novartis, Basle, Switzerland; 100 ng/ml in Dulbecco PBS (DPBS) and 1% (w/v) bovine serum albumin; final concentration of CSF2 after dilution in the drops ¼ 10 ng/ml) or 5 ll of the vehicle used to dilute CSF2 (control treatment). The concentration of CSF2 was chosen based on its effectiveness for increasing embryonic survival after transfer into recipient females [25] .
Embryo Transfer
Grade 1 expanded blastocysts [37] were harvested from culture drops at Day 7 of development and loaded into 0.25-ml straws in 250 ll HEPES-TALP [38] supplemented with 10% (v/v) fetal calf serum and 50 lM dithiothreitol (Sigma-Aldrich). Each straw contained one embryo and was inserted horizontally into a portable incubator (AI gun warmer; EM Tools, Rusk, TX) at 38.58C and transported to the Dairy Unit at the University of Florida (Hague, FL).
For each replicate, ovulation of 5-26 cows was synchronized using a modified OvSynch 56 protocol [39] . Cows received intramuscular injections of 100 lg gonadotropin-releasing hormone (GnRH; Cystorelin; Merial) on the morning of Day À8 (Day 0 ¼ expected day of ovulation), 25 mg prostaglandin F 2a (Lutalyse; Zoetis) on the morning and afternoon of Day À2, and 100 lg GnRH on the afternoon of Day À1. Cows having a detectable corpus luteum on Day 7, as determined by ultrasonography using a Hitachi Aloka 500 ultrasound with 5 MHz linear array transducer, were randomly assigned to receive a CSF2-treated or control embryo. The embryo was transferred transcervically to the uterine horn ipsilateral to the ovary containing the corpus luteum using an embryo transfer pipette after application of a local epidural block using 2% (w/v) lidocaine. The protocol for animal research was approved by the University of Florida Institutional Animal Care and Use Committee.
Embryo Recovery
Embryos were recovered at Day 15 of development by flushing the uterine horn ipsilateral to the corpus luteum with DPBS containing 1% (v/v) polyvinyl alcohol (DPBS-PVA). Flushing medium was introduced into the uterus by means of a 20 French Foley catheter inserted transcervically using a stainless steel blunt stylet placed inside the catheter. After placement, the stylet was withdrawn and the catheter held in place by inflation of a cuff at the end of the catheter. The flushing procedure, which involved introduction of 60 ml into the uterus and recovery of fluid through the catheter, was repeated four times or until an embryo was recovered.
Embryos recovered by flushing were assessed by light microscopy for stage of development, length, presence of an embryonic disk, and whether the embryo was recovered intact or in pieces. All recovered embryos were at the filamentous stage of development. If found, the embryonic disk was dissected from the EEM using a sterile scalpel and tweezers. The EEM was snap frozen in liquid N 2 in a minimal amount of DPBS-PVA and stored at À808C until extraction of genomic DNA (gDNA) and total RNA. The fluid from the first uterine flush was centrifuged for 10 min at 1000 3 g and stored at À208C.
The total number of Day 15 embryos collected using the procedures described above was 16. An additional 14 Day 15 embryos of either filamentous or tubular stages that had been treated with CSF2 or vehicle were used for the analysis of sex and CSF2 effects on embryo length and IFNT accumulation in the uterus. These embryos were produced using a variety of bulls. Further details of production of these embryos were reported by Loureiro et al. [27] . The addition of these samples was used to increase the power of the analysis for length and IFNT accumulation in the uterus. As a result, the total number of observations per treatment for length and IFNT accumulation was seven or eight for male embryos and six to eight for female embryos. To determine whether sex effects on length and IFNT in embryos occur earlier in development, we analyzed effect of sex on 10 Day 14 control (i.e., not treated with growth factors during culture) embryos. Details of the procedures for production of the Day 14 embryos are reported elsewhere [40] .
IFNT Assay
Amount of biologically active IFNT in uterine flushings was determined by measuring the inhibition of vesicular stomatitis virus induced lysis of MadinDarby bovine kidney cells as described elsewhere [41] . Antiviral activity was converted to units of IFN (IU/ml) by comparing inhibition to that achieved with a human IFNA standard (Millipore).
Data on embryo length and uterine IFNT were analyzed by least-squares analysis of variance using the GLM procedure of the Statistical Analysis DOBBS ET AL. System version 9.3 (SAS Institute Inc.) with effects of sex, treatment, and sex 3 treatment.
Extraction of gDNA and Total RNA Genomic DNA and total RNA from the embryos collected uniquely for this experiment were extracted using the AllPrep DNA/RNA Mini kit (Qiagen). Embryos were disrupted with Buffer RLT Plus containing b-mercaptoethanol, vortexed for 30 sec, and homogenized through QIAshredder columns (Qiagen). Homogenized lysate was separated into gDNA and total RNA following manufacturer's guidelines. Both gDNA and total RNA were stored at À808C until processing. Total RNA quantity, quality, and integrity were determined using an Agilent Bioanalyzer 2100. RNA integrity was .7.5 for all samples and there was an absence of DNA contamination of RNA samples. Concentration of gDNA was quantified by Nanodrop spectrophotometer (Thermo Fisher Scientific) with all samples being .76 ng/ll.
Sexing by PCR
Sex for each embryo was determined by endpoint PCR with previously published primers specific for BOV97M located on the Y chromosome (forward: 5 0 -GAT CAC TAT ACA TAC ACC ACT-3 0 ; reverse: 5 0 -GCT ATG CTA ACA CAA ATT CTG-3 0 ) and an autosomal satellite DNA sequence (forward: 5 0 -TGG AAG CAA AGA ACC CCG CT-3 0 ; reverse: 5 0 -TCG TCA GAA ACC GCA CAC TG-3 0 ) [42] . Master mix was composed of 103 PCR buffer, 2.5 mM dNTP, 50 mM MgCl 2, 10 lM of primers, and 0.2 ll of Taq DNA polymerase (5 U/ll) (Invitrogen). A total of 2 ll of DNA sample was combined with the 10.2 ll master mix and subjected to PCR for 7 min at 958C and 40 cycles of 30 sec at 958C, 30 sec at 578C, and 30 sec at 728C, followed by a final extension at 728C for 7 min. Each sample (5 ll) was analyzed on a 1.5% (w/v) agarose gel with 5 ll ethidium bromide (10 mg/ml) using a 100-bp ladder (New England Biolabs). A male control consisted of fibroblast or sperm DNA and a female control consisted of DNA extracted from an ovary.
Analysis of Transcriptome
Total RNA from three female control embryos, three female CSF2-treated embryos, two male control embryos, and four male CSF2-treated embryos (selected at random from the pool of available embryos) were subjected to T7 RNA amplification using the RiboAmp HS Plus RNA amplification kit as previously described [43] [44] [45] . The amplified RNA (aRNA) was labeled using the Universal Linkage System (ULS; Kreatech Biotechnology) with either ULS-Cy3 or ULS-Cy5 [44, 46] . Microarray analysis of labeled aRNA was performed using an Agilent 4 3 44 000 slide microarray designed by EmbryoGENE to overrepresent genes expressed by the bovine preimplantation embryo and performed as described elsewhere [43] [44] [45] [46] . Raw transcriptome data were deposited with the Gene Expression Omnibus and can be accessed using accession number GSE55364.
Analysis of Transcriptome Microarray Data
Microarray images were submitted to BioDiscovery Inc. to generate separate datasets for each color (Cy3 and Cy5). In addition, spots were aligned to the corresponding GenePix array list, which describes size, position, and label of each spot on the array, and examined for removal if spots on the array were abnormally large or contained a blemish. The mean intensity for each spot was corrected by subtracting the mean intensity of background values for each sample to remove background noise. Mean intensity was then transformed by log2 and analyzed using JMP Genomics (SAS). Data were normalized with locally weighted scatter plot smoothing (LOESS) normalization for dye-dye correction followed by quantile normalization for between-array correction. Genes that were differentially expressed were determined by analysis of variance with a model that included effects of treatment, sex, and treatment 3 sex. P values for significant genes were then adjusted for multiple testing by SGoFþ estimation, as described by Carvajal-Rodriguez and Uñ a-Alvarez [46] . All genes that had an adjusted P value of ,0.05 and where the difference in expression was !1.5 or 0.67 were considered differentially expressed.
Ingenuity pathway analysis software (Ingenuity Systems) was used to determine gene ontologies and to identify biological processes that were predicted to be regulated by the observed changes in gene expression. Canonical pathways and biological processes were considered significant at P , 0.05. Only ontologies and biofunctions with three or more differently expressed genes were used for analysis. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used to determine gene ontologies and functions in which differentially expressed genes (DEGs) were overrepresented at P , 0.05 [47] . We used iPath 2.0 to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways that contained overrepresentation of DEGs [48] .
Validation of Transcriptome Microarray by PCR
Validation of microarray gene expression was accomplished by quantitative RT-PCR (qPCR) of the samples of embryo RNA used for RNA microarray. Samples were treated with 1 ll (2 U) of DNase I (New England Biolabs) in a total volume of 20 ll at 378C for 30 min to remove DNA, and then incubated at 758C for 15 min to denature DNase. DNase-treated RNA was then reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Reverse transcription occurred using random hexamer primers and involved incubation at 258C for 10 min, 378C for 120 min, and 858C for 5 min. The cDNA was stored at À208C until further use. Negative controls for real-time PCR were also performed by incubation without reverse transcriptase.
Complementary DNA was utilized for real-time PCR analysis using conditions described previously [24] . The DC T value was determined by subtracting the geometric mean [49] of the C T for three housekeeping genes from the C T value of the sample. The housekeeping genes GAPDH, SDHA, and YWHAZ were utilized because expression is stable over preimplantation development [28, 50] . Primer sequences are in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org). The primers for XIST [51] , GAPDH [28] , SDHA [50] , and YWHAZ [50] are described elsewhere and other primers were designed using PrimerQuest (IDT DNA). The accuracy of results from microarray analysis was determined by calculating the Pearson correlation coefficient between the DC T value as determined by PCR with the normalized intensity as determined by microarray analysis.
Analysis of Methylome
The methylome was analyzed for a subset of embryos used for analysis of the transcriptome (three female control embryos, three female CSF2-treated embryos, two male control embryos, and two male CSF2-treated embryos). The gDNA was digested by MseI and then with methylation-sensitive enzymes HpaII, HinpII, and AciI. Products were amplified, labeled, and then subjected to microarray analysis using an Agilent array designed by EmbryoGene. Raw methylome data can be accessed from Gene Expression Omnibus using accession number GSE55873.
For fragmentation of gDNA, gDNA was diluted to 10 ng in 15 ll and spiked with a 1.5-ll mix of specific DNA sequences sensitive to the restriction enzymes to serve as a control for subsequent qPCR. gDNA was digested with 0.5 ll (5 U) MseI in a volume of 50 ll for 16 h at 378C followed by inactivation for 20 min at 658C. MseI-digested gDNA was precipitated using 1 ll 3 M sodium acetate and linear acrylamide (Life Technologies). The gDNA pellet was reconstituted in 5 ll H 2 O. MseI designed linkers were ligated to the 5 0 and 3 0 end of the digested gDNA using 1.0 ll (5 U) T4 DNA ligase and 10 mM ATP at 158C for 16 h. Linker-ligated gDNA was digested by adding 0.5 ll (5 U) HpaII and 0.5 ll (5 U) HinpII at 378C for 12 h. After 12 h, an additional restriction enzyme, 0.5 ll (5 U) AciI, was added to each sample and incubated at 378C for 4 h followed by heat inactivation at 808C for 10 min. Digestion efficiency was verified using qPCR on a Roche Lightcycler 2.0 with HpaII-, AciI-, and HinpII-specific primers. A difference of at least five cycle thresholds was required to proceed to DNA precipitation. Because some samples did not exceed this threshold, all gDNA samples were subjected to one more round of enzyme digestion with the aforementioned enzymes for 4 h at 378C. Digested DNA was precipitated and amplified by ligation-mediated PCR using MseI primers that bind to the MseI ligated linkers. A second PCR was performed on the amplified digested gDNA using only the 3 0 MseI primer followed by PCR purification using a PCR purification kit (Qiagen). DNA was eluted in 43.5 ll elution buffer. MseI linkers were removed using 0.5 ll MseI (10 U/ll) at 378C for 16 h followed by heat inactivation at 658C for 20 min. The gDNA was then repurified using the PCR purification kit and eluted in 43.5 ll elution buffer.
Digested gDNA was labeled as described for the procedure to label RNA. The gDNA was purified using the QIAquick PCR purification kit (Qiagen) and eluted in 23.5 ll elution buffer. Yield and labeling efficiency of gDNA was determined using the Nanodrop 1000 spectrophotometer. The degree of labeling of gDNA with Cy3 was between 1.8% and 3.5% and labeling with Cy5 was between 0.8% and 2.5%.
Labeled DNA was hybridized to an Agilent 2 3 444 000 microarray slide designed by EmbryoGENE. The microarray DNA probes included at least one CpG and were designed based on a methylation-specific deep sequencing analysis of the bovine genome that generated 1.2 million reads from genomic libraries from Day 7 blastocysts and Day 12 elongated embryos [52] 
sex) were combined with 25 ll of bovine Hybloc DNA (1 mg/ml; Applied Genetics), 130 ll of 23 Hi-RPM (Agilent), and 1003 blocking agent (Agilent); the final volume was brought to 195 ll with nuclease-free water. This solution was heated for 3 min at 958C and 30 min at 378C. Samples were then centrifuged at 10 000 3 g and mixed with 65 ll Agilent-CGH Block solution (Agilent). A total of 245 ll of each sample was placed into the slide and hybridized at 658C while rotated at 10 rpm for 40 h. Following incubation, slides were washed according to the manufacturer's procedure and scanned as described previously.
Analysis of Methylome Array
DNA microarrays were analyzed using the limma package of Bioconductor [53] . Raw data were normalized using within-array LOESS normalization followed by between-array quantile normalization. Normalized data were then fit to a linear model before being subjected to an empirical Bayes correction. Mean intensity of each spot on the array was transformed by log2, and P values were determined using a moderated t-statistic [53] . Regions with an estimated absolute fold change above 1.5 or below 0.67 and a P , 0.05 were considered as differentially methylated. Development of visualization tools was designed to analyze the quality of both overall genomic and spiked-in gDNA control digestion. Differentially methylated regions (DMRs) were categorized based on CpG island density [54] , length [55] , and distance [56] ; location of the DMR in the genome; and types of repeated elements [57] .
Regions of each chromosome that had a frequency of DMRs caused by CSF2 greater than expected were determined by chi-square analysis. For each chromosome, 5-Mbp segments of the genome were examined for observed number of differentially expressed probes. The expected frequency for chisquare analysis was calculated as the number of probes in the 5-Mbp segment times the overall percentage of probes that were differentially methylated. The analysis was performed using sliding windows of 5 Mbp that shifted by 500 kbp at a time until reaching the end of the chromosome. Analysis was performed separately for female and male embryos.
RESULTS
Embryo Length and IFNT Accumulation in the Uterus
Sex of each embryo was determined by PCR (Fig. 1A) . Embryo length and amount of IFNT in uterine flushings at Day 15 were each affected by the treatment 3 sex interaction (Fig.  1B , P , 0.05). For embryos not treated with CSF2, female embryos were longer than male embryos and there was greater accumulation of IFNT in the uterus than for male embryos. In females, CSF2 decreased embryo size and IFNT accumulation, whereas in males, CSF2 increased embryo size and IFNT accumulation. As a result, male embryos treated with CSF2 were larger and secreted more IFNT than female embryos treated with CSF2.
Another set of embryos collected at Day 14 of gestation was examined for sex differences. In this case, involving embryos not treated with growth factors, there was no difference in length between female and male embryos (19.4 6 11.1 and 23.6 6 11.1 mm respectively, n ¼ 5 for each sex). Thus, it is likely that differences in length between sexes in control embryos at Day 15 represent earlier onset of elongation in female embryos rather than an inherently larger size in females.
Differentially Expressed Genes
The list of DEGs observed with microarray analysis is presented in Supplemental Data S1. A Venn diagram illustrating numbers of DEGs is presented in Figure 2 .
Among control embryos, a total of 537 genes differed in expression between female and male embryos. This represents 1.5% of the probes on the array. A total of 39 of the 537 genes that were differentially expressed between female and male embryos were located on the X chromosome (7.3% of the DEGs). This incidence was greater (P , 0.001) than the expected number of DEGs on the X chromosome because of chance (3.8% of the probes on the array represent genes on the X chromosome). For DEGs located on the X chromosome, 9 were downregulated in the female whereas 30 were upregulated, with 5 of those 30 (16.7%) having a 2-fold or higher change.
Given effects of treatment 3 sex on IFNT accumulation in the uterus, particular attention was paid to expression of IFNT. There were, however, no effects of sex, treatment, or sex 3 treatment on expression of this gene (Supplemental Data S1).
Using DAVID, genes that were differentially expressed because of sex were overrepresented in 38 gene ontology terms (P , 0.05), with terms related to mitochondrial function, protein ubiquitination, electron transport, and translation being prominent (Supplemental Data S2). KEGG pathway functional annotation terms that were overrepresented in the set of sex DEGs were those for oxidative phosphorylation (Supplemental Fig. S1 , P , 0.02) and ribosome (P , 0.05). Using IPA software, three canonical pathways having a minimum of three DEGs were identified: EIF2 signaling (P , 0.0002), mitochondrial dysfunction (P , 0.0003), and fatty acid boxidation 1 ( Fig. 3A ; P , 0.007). This finding was reiterated when the list of DEGs was analyzed by iPATH 2.0 (Supplemental Fig. S2 ) [48] .
The biofunction analysis feature of IPA was used to predict cellular processes that would experience a change in activation as a result of changes in gene expression between female and male embryos. It predicted that female embryos were likely to be less active than male embryos in expression of protein (P , 0.01); translation (P , 0.01), and translation of protein (P , 0.01; Fig. 3B) ; metabolism of protein (P , 0.001; Fig. 3C ); and transport of lipid (P , 0.05; Fig. 3D ).
CSF2 caused differential expression of 54 genes in females and 94 genes in males (Supplemental Data S1). A large proportion of genes regulated by CSF2 in both females and males were among the set of genes whose expression differed between male and female control embryos. In particular, 31 of 54 DEGs in females (57%) and 48 of 94 DEGs in males (51%) were also regulated by sex in control embryos. For both the female and male, the number of significant DEGs located on the X chromosome was no greater (4 and 6 respectively) than what would be expected because of chance (2.1 and 3.6 respectively). Only seven DEGs were regulated by CSF2 in both females and males and regulation was always in opposite directions. For example, expression of HSP90B1 was increased by CSF2 in females and decreased in males (Fig. 2) .
Among the genes regulated by CSF2 in females, only 25 of 54 were annotated. These genes were overrepresented in one DAVID gene ontology, generation of precursor metabolites and energy (P , 0.05; Supplemental Data S2), and one KEGG pathway, oxidative phosphorylation (P , 0.01). There were no significant IPA canonical pathways or cellular processes identified by the biofunction analysis feature of IPA. In males, only 60 of 94 were annotated. There was no significant DAVID gene ontology, KEGG pathways, or IPA canonical pathways containing these DEGs. However, the biofunction analysis feature of IPA indicated CSF2 decreased metabolism of protein (P , 0.05) and increased invasion of cells (P , 0.05) in male embryos (Fig. 4) .
The accuracy of microarray results was evaluated by determining the correlation between intensity of hybridization signal in microarray analysis with the DC T value from qPCR for nine genes significantly affected by either CSF2 within sex or between sexes with control-treated samples (Supplemental Table S2 ). For seven of nine genes, an increase in hybridization signal was negatively correlated with DC T (i.e., positively DOBBS ET AL. correlated with amount of mRNA). The correlation was significant for six of nine genes.
Methylome
The list of DMRs detected using a bovine methylome array is presented in Supplemental Data S3. A Venn diagram illustrating numbers of DMRs is presented in Figure 5 . 
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(P , 0.001) than the expected number of DMRs on the X chromosome because of chance (2.8% of the probes on the array were on the X chromosome).
Treatment with CSF2 from Day 5 to Day 7 caused hypermethylation at Day 15 of 6227 probes in females and 9842 probes in males, and caused hypomethylation of 3292 probes in females and 9322 probes in males (Fig. 5) . In the female, 6102 (64%) of these DMRs were located in the open sea, 2452 (25.7%) in the shelf, 787 (8.2%) in the shore, and 181 (1.9%) within a CpG island, whereas 2 DMRs were not classified (Supplemental Data S3). In the male, 11 931 (62%) DMRs were located in the open sea, 4790 (25%) in the shelf, 1641 (8.5%) in the shore, and 792 (4.1%) within a CpG island, whereas 10 DMRs were not classified (Supplemental Data S3).
Of the 9519 DMRs regulated by CSF2 in females, 2766 (29.1%) were DMRs whose methylation status in controls differed between females and males. Similarly, of the 19 164 DMRs regulated by CSF2 in males, 6597 (34.4%) were regions that were differentially methylated between females and males in control embryos. Thus, a greater percentage of methylation sites regulated by CSF2 are also modified by sex than is the case for the entire genome (7.6%). A total of 1186 DMRs were affected by CSF2 in both females and males. Of these, 773 (65.2%) were regulated in the opposite direction (hypermethylation in one sex and hypomethylation in the other sex).
Chi-square analysis was used to identify 1) whether spatial distribution of DMRs on regions of each chromosome was nonrandom (as would be expected if DMRs were under regulation) and 2) whether the chromosomal regions that were differentially methylated by CSF2 in females were distinct from those regions in males. For each chromosome, there were regions that contained hypermethylation and/or hypomethylation due to CSF2 that was more frequent than would be expected because of chance if DMRs were randomly distributed across the chromosome. Moreover, the regions of differential methylation caused by CSF2 were usually different for females than for males, as is illustrated for BTA 1 in Figure  6 and for other chromosomes in Supplemental Data S4. 
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DISCUSSION
It is well known that alterations in the maternal environment during prenatal life can have long-term effects on the physiology and health of the offspring and that the nature of these effects differs between females and males [6] [7] [8] 17] . From an evolutionary perspective, sexual dimorphism in developmental programming probably reflects the differential value of males and females for sexual propagation [18] . Although the phenomenon has been well described, the mechanism by which sexual dimorphism in developmental programming is achieved has hitherto been unknown. Current findings lead to the hypothesis that sexual dimorphism results because female and male embryos respond differently to environment-driven alterations in secretion of maternally derived embryokines. In this model, the reproductive tract uses altered secretion of embryokines as a signal transducer to transmit information about the maternal environment to the embryo. For certain signals, as shown here for CSF2, male embryos respond differently than do female embryos, so that the deviation in the developmental trajectory in response to environmental change varies between sexes.
The evidence for this idea comes from the findings that exposure of preimplantation embryos to CSF2 for a 2-day period from Day 5 to Day 7 of development results in changes in embryonic growth, gene expression, and DNA methylation in the EEM of embryos later in pregnancy, Day 15 of development. It is at this stage of pregnancy that the bovine embryo first signals its presence to the mother through the secretion of the antiluteolytic molecule IFNT [34] . Secretion of IFNT is coupled to a process of embryo elongation where the embryo undergoes a rapid increase in length from about 2-5 mm in length on Day 14 to about 150 mm in length on Day 16 [58] . Elongation is a prerequisite for the upregulation of IFNT secretion in the ruminant [59] .
Present results suggest that, in the absence of prior exposure to CSF2, the female embryo is larger and secretes more IFNT into the uterus than the male embryo. The larger size of female embryos probably reflects earlier onset of elongation rather than an inherently larger size, because there was no difference in embryo length between female and male embryos at Day 14, around the time when elongation is being initiated. Similar lacks of difference between female and male embryos in length   FIG. 3 . Biological processes predicted to vary with sex in control embryos. A) The canonical pathways containing an overrepresented number of DEGs (P , 0.05). Only pathways with three or more genes are shown. Gene symbols represent DEGs for each pathway; genes in red were upregulated in females and genes in green were upregulated in males. B-D) Analyses of predicted differences in cellular function between female and male embryos. Genes in red were upregulated in females and genes in green were upregulated in males. Blue lines represent genes in which the observed change in gene expression are predicted to inhibit the biological function, yellow lines represent genes where the effect of differential expression is inconsistent with the predicted stage of the process, and gray lines represent relationships that are not predicted. Biological processes in blue are predicted to be inhibited. Analysis indicates that female embryos were likely to be less active in expression of protein (P , 0.01), translation (P , 0.01), and translation of protein (P , 0.01) (B); metabolism of protein (P , 0.001) (C); and transport of lipid (P , 0.05) (D) than male embryos.
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as well as IFNT secretion were observed for embryos produced in vivo [60] . In contrast, IFNT mRNA was greater for female embryos produced in vitro than male embryos at Day 14 [61] . Additionally, a report using red deer showed that female filamentous embryos produced more IFNT than male embryos at the same stage [62] . By Day 16, male embryos have been reported to be longer than female embryos, with differences greater for embryos produced in vivo than for those produced in vitro and subsequently transferred to recipients [63] .
Despite its larger size, analysis of the transcriptome reveals that the female embryo is less active with respect to oxidative phosphorylation, with NDUFA11, NDUFS7, UQCRC1, COX6A1, and ATP6V1B2 downregulated in females and only NDUFB1 upregulated. Gene expression in female embryos also indicates decreased translation and metabolism. The decreased metabolism of female embryos could reflect the earlier onset of elongation and reduced metabolism as the rate of growth decreases at the end of the elongation period. However, female embryos have less mtDNA copies as early as the blastocyst stage [19, 64] and may simply be less metabolically active than males.
Exposure to CSF2 from Day 5 to Day 7 reverses differences between female and male embryos by decreasing length and IFNT release in female embryos while increasing it in males. Concomitantly, CSF2 programmed gene expression of female embryos differently than for male embryos. In most cases, genes whose expression at Day 15 was altered by prior exposure to CSF2 from Day 5 to Day 7 were different for female embryos than for male embryos. In the few cases where the same gene was altered in expression by CSF2 in females and males, regulation was in opposite directions. A similar phenomenon was observed when examining characteristics of the methylome: DMRs tended to be different for females and males, and when the same were most often regulated in opposite directions.
CSF2 is a good candidate for transmitting information about the maternal environment to the embryo. Produced by the luminal and glandular epithelium of the endometrium [22] , expression of CSF2 is sensitive to perturbation in response to the maternal environment. In particular, expression of CSF2 in the bovine endometrium was reduced in obese cows [31] , whereas accumulation of CSF2 or steady-stage amounts of CSF2 mRNA in the endometrium was increased by deposition of semen in humans, pigs, and mice [32, 65, 66] . One DOBBS ET AL. component of semen responsible for increased expression of CSF2 in the mouse is Tgfb [32] .
In cattle, administration of progesterone to cause premature elevation of circulating progesterone concentrations after ovulation accelerates the timing of embryo elongation [67, 68] . Perhaps progesterone regulates elongation by altering oviductal or endometrial secretion of embryokines like CSF2 that can regulate the process of embryo elongation. Consistent with this idea is the observation that progesterone alters the endometrial transcriptome [69] .
Other embryokines exist that could potentially be involved in developmental programming. Among the molecules in the cow that have been reported to affect development to the blastocyst stage are IGF1 [70] , TGFB [71] , LIF [71] , and FGF2 [35] . Other embryokines, including IGF1 [72] and DKK1 [73] , can improve competence of the bovine blastocyst to establish pregnancy after transfer to recipient females. Although each of these molecules can affect embryonic development, it is not known whether their actions on the embryo also depend upon sex.
It is also not clear how the sex-dependent changes in embryo function seen here affect the survival of the embryo or the physiology of the resultant neonate. In female embryos, treatment with CSF2 from Day 5 to Day 7 increases the proportion of embryos that establish and maintain pregnancy after transfer to recipient females [25] . Thus, the reduction in embryo length and IFNT secretion at Day 15 in female embryos is not inimical to embryo survival. Among the genes upregulated by CSF2 in females were several candidates related to oxidative phosphorylation, and it may be that increased capacity of the EEM to metabolize energy substrates contributes to the embryo's survival. There is no comparable information about the effects of CSF2 on subsequent survival of male embryos. CSF2 altered gene expression in male embryos in a manner suggesting decreased metabolism of protein and increased invasion of cells in male embryos, and these actions could potentially limit embryo survival.
There is also no information regarding the consequences of CSF2 treatment from Day 5 to Day 7 on characteristics of the resultant calves. Data that CSF2 causes sex-specific changes in the methylome suggest the possibility of long-term changes that could extend into fetal or postnatal life.
An important unresolved question is the molecular basis for the differential response of female and male embryos to CSF2. One facet of this response may involve the nature of genes regulated by CSF2, which include an overrepresentation of genes and CpGs that are also regulated by sex. Over 50% of the DEGs and 35% of the DMRs regulated by CSF2 were among the small pool of genes and DMRs that were regulated by sex. One possibility is that CSF2 regulates transcription factors and other signaling systems responsible for sex-regulated differences in gene expression. Alternatively, a large fraction of genes regulated by sex have transcription factors or regulatory elements also regulated by CSF2.
A total of 7.3% of genes that were differentially expressed between control female and male embryos were located on the X chromosome. Similarly, 3.9% of DMRs due to sex were on the X chromosome. Although the incidence of regulation of Xlinked genes was higher than expected because of chance, most of the differences between female and male embryos in the FIG. 6 . Nonrandom clustering of differentially methylated probes caused by CSF2 in female and male embryos-example from bovine chromosome 1. The probability that the actual number of differentially methylated probes (DMRs) in a 5-Mbp segment was greater than because of chance was determined by chi-square analysis after calculating the expected frequency of DMRs if location of DMRs were randomly distributed throughout the genome. The analysis was performed using sliding windows of 5 Mbp that shifted by 500 kbp at a time until reaching the end of the chromosome. The figure shows the chi-square value for 5-Mbp regions where the number of DMRs caused by CSF2 was greater than expected because of chance. Bars of orange and red represent regions for female embryos where the number of hypermethylated and hypomethylated DMRs was greater than expected because of chance. Blue and green bars represent regions for male embryos where the number of hypermethylated and hypomethylated DMRs was greater than expected because of chance.
transcriptome and methylome occurred because of regulation of autosomal chromosomes. In contrast, 18.1% of the DEGs between female and male blastocysts at Day 7 were on the X chromosome and 47% of the DEGs with a fold change .1.6 were on the X chromosome [19] . Changes in the relative proportion of DEGs on the X chromosome between Days 7 and 15 reflect X-chromosome inactivation, which starts as early as the blastocyst stage and is largely complete by Day 14-15 [19, 61, 74] . Given that most genes regulated by sex at Day 15 are not on the X chromosome, it is not surprising that sexdependent actions of CSF2 on gene expression also occurred primarily for autosomal regions of the genome.
One limitation to this study was the low number of replicates for analysis of the transcriptome and methylome. Nonetheless, the pattern of treatment effects, with a treatment 3 sex interaction, was similar to results for embryo length and IFNT accumulation that involved more animals. Moreover, the differences observed, including a preponderance of CSF2 regulated genes being in the subset regulated by sex, were very unlikely to have occurred because of chance. It is possible that treatment effects on the transcriptome and methylome are a reflection, at least in part, of treatment differences in embryo length because there were large differences in length between groups. Thus, treatment 3 sex effects on the transcriptome or methylome could be caused to some extent by treatment 3 sex effects on the time course of embryo elongation. There was no effect of treatment, sex, or treatment 3 sex on expression of IFNT, implying that the effects of treatment 3 sex on accumulation of IFNT in the uterus were a result of differences in embryo length and not gene expression per cell.
In conclusion, we present data to indicate a mechanism for sexual dimorphism in developmental programming [5, 6, [15] [16] [17] . In particular, treatment of preimplantation embryos with the maternally derived cytokine CSF2 from Day 5 to Day 7 of development changes subsequent development so that, at a later stage of pregnancy, Day 15, embryonic development is altered with respect to length, secretion of the pregnancy signal, IFNT, the transcriptome, and the methylome. Alterations in these characteristics caused by CSF2 were different between female and male embryos, with effects being often in the opposite direction. We conclude that alterations in secretion of maternal regulatory factors caused by change in maternal environment could modify the developmental program of the female embryo differently than for the male embryo.
